• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists - Product Image

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists

  • Published: February 2012
  • Region: Global
  • 168 Pages
  • GBI Research

FEATURED COMPANIES

  • Amylin Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Merck & Co Inc
  • Novo Nordisk
  • Sanofi
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research ""Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists"" which provides insights into diabetes therapeutics sales and price forecasts until 2017. The report also examines the global diabetes therapies’ treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region, and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of the two diabetes therapeutic indications, which are Type 1 and Type 2 diabetes. In addition, it includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

The global diabetes market is growing rapidly READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Diabetes Therapeutics Market to 2017 - Introduction
2.1 GBI Research Report Guidance

3 Diabetes Therapeutics Market to 2017 - Market Overview
3.1 Introduction
3.2 Three Major Unmet Needs Prevalent in the Diabetes Market
3.2.1 Complications like Heart Risks are Associated with Some of the Oral Anti-Diabetic Drugs
3.2.2 Patients on Insulin Analogues are Prone to Carcinogenic Effects
3.2.3 Poor Patient Compliance with Anti-Diabetic Drug Therapy
3.3 Revenue
3.4 Annual Cost of Therapy (ACT)
3.5 Treatment Usage Patterns
3.5.1 Prevalence Population
3.5.2 Treatment Seeking Population
3.5.3 Diagnosed Population
3.5.4 Prescription Population
3.6 Drivers and Restraints of the Diabetes Therapeutics Market
3.6.1 Drivers of the Diabetes Market
3.6.2 Restraints for the Diabetes Market
3.7 Branded vs. Generic Market Share in the Global Diabetes Market

4 Diabetes Therapeutics Market to 2017 - Geographical Landscape
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.1.3 Treatment Usage Patterns
4.2 Top Five Countries of Europe
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Patterns
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Patterns

5 Diabetes Therapeutics Market to 2017 - Therapeutic Landscape
5.1 Type 1 Diabetes Market
5.1.1 Introduction
5.1.2 Symptoms
5.1.3 Treatment
5.1.4 Unmet Needs
5.1.5 Branded vs. Generic Market Share in the Type 1 Diabetes Market
5.1.6 Revenue
5.1.7 Annual Cost of Therapy (ACT)
5.1.8 Treatment Flow Algorithm for Type 1 Diabetes
5.1.9 Treatment Usage Patterns
5.1.10 Drivers and Restraints for the Type 1 Diabetes Market
5.2 Type 2 Diabetes Market
5.2.1 Introduction
5.2.2 Symptoms
5.2.3 Treatment
5.2.4 Unmet Needs
5.2.5 Branded vs. Generic Market Share in the Type 2 Diabetes Market
5.2.6 Revenue
5.2.7 Annual Cost of Therapy
5.2.8 Treatment Flow Algorithm for Type 2 Diabetes
5.2.9 Treatment Usage Patterns
5.2.10 Drivers and Restraints for the Type 2 Diabetes Market

6 Diabetes Therapeutics Market to 2017 - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Type 1 Diabetes
6.1.2 Research and Development Pipeline - Type 2 Diabetes
6.2 Innovations in Diabetes Treatment
6.2.1 Insulin in Pills (Oral Delivery)
6.2.2 Promising Treatments for Diabetic Retinopathy
6.2.3 Biomarkers in Diabetes
6.2.4 Combination Drugs are an Important Part of the Diabetes Pipeline
6.2.5 Cellular Activation Therapy (CAT)
6.3 Drug Delivery in Diabetes
6.3.1 Factors Determining Preference for Drug Delivery
6.3.2 Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable
6.3.3 Innovation in Drug Delivery Systems
6.4 Profiles of Promising Drugs in the Diabetes Market
6.4.1 rhGAD65 (Diamyd)
6.4.2 Bydureon
6.4.3 DiaPep277
6.4.4 Otelixizumab
6.4.5 Alogliptin
6.4.6 Oral-Lyn
6.4.7 Dapagliflozin
6.4.8 Canagliflozin
6.4.9 MB07803

7 Diabetes Therapeutics Market to 2017 - Competitive Landscape
7.1 Diabetes Market Overview
7.1.1 Human Insulin Products and Oral Antidiabetic Drugs like Actos Group (Actos and Actoplus Met) and Lantus Have Led Market Growth
7.2 Market Share Analysis - Diabetes
7.2.1 Market Share Analysis by Company - 2010
7.2.2 Market Share Analysis by Company - 2017
7.3 Market Share Analysis by Class for the Anti-Diabetic Drugs
7.3.1 Market Share Analysis by Drug Class - 2010
7.3.2 Market Share Analysis by Drug Class - 2017
7.4 Competitive Profiling
7.4.1 Novo Nordisk
7.4.2 Sanofi
7.4.3 Takeda
7.4.4 Eli Lilly
7.4.5 GlaxoSmithKline (GSK)
7.4.6 Merck & Co Inc
7.4.7 Amylin Pharmaceuticals

8 Diabetes Therapeutics Market to 2017 - M&A Landscape
8.1 Overview
8.2 Mergers and Acquisitions (M&A)
8.2.1 Strategic Consolidation
8.2.2 M&A Deals by Value
8.2.3 Major Mergers and Acquisitions
8.2.4 M&A Deals by Geography
8.2.5 M&A Deals by Indication
8.3 Licensing Agreements
8.3.1 Licensing by Geography
8.3.2 Major Licensing Agreements
8.3.3 Licensing Agreements by Indication
8.3.4 Licensing Agreements by Value
8.4 Co-Development
8.4.1 Co-Development by Geography
8.4.2 Major Co-Development Deals
8.4.3 Co-Development by Indication
8.4.4 Co-Development by Value

9 Diabetes Therapeutics Market to 2017 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Forecasts
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

1.1 List of Tables
Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2003-2010
Table 2: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2010
Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2003-2010
Table 6: Diabetes Therapeutics Market, The US, Revenue ($bn), 2003-2010
Table 7: Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017
Table 8: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2010
Table 9: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017
Table 10: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2003-2010
Table 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017
Table 12: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue, $bn, 2003-2010
Table 13: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2010-2017
Table 14: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2010
Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017
Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2003-2010
Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2017
Table 18: Diabetes Therapeutics Market, Japan, Revenues ($bn), 2003-2010
Table 19: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017
Table 20: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2010
Table 21: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017
Table 22: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2003-2010
Table 23: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017
Table 24: Diabetes Therapeutics Market, Type 1 Diabetes Market, Types of Insulin Regimen
Table 25: Type 1 Diabetes Market, Global, Revenues ($bn), 2003-2010
Table 26: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 27: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010
Table 28: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 29: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010
Table 30: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017
Table 31: Type 2 Diabetes Market, Global, Revenues ($bn), 2003-2010
Table 32: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 33: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010
Table 34: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 35: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010
Table 36: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017
Table 37: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011
Table 38: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Pre-Clinical, 2011
Table 39: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011
Table 40: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011
Table 41: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011
Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011
Table 43: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011
Table 44: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, IND Filed, 2011
Table 45: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011
Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011
Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011
Table 48: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011
Table 49: Diabetes Therapeutics Market, Factors Determining Preference of Drug Delivery in Diabetes
Table 50: Diabetes Therapeutics Market, Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable
Table 51: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2011
Table 52: Diabetes Therapeutics Market, Sanofi, Pipeline Products, 2011
Table 53: Diabetes Therapeutics Market, Takeda, Pipeline Products, 2011
Table 54: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2011
Table 55: Diabetes Therapeutics Market, GSK, Pipeline Products, 2011
Table 56: Diabetes Therapeutics Market, Merck, Pipeline Products, 2011
Table 57: Diabetes Therapeutics Market, Amylin, Pipeline Products (%), 2010
Table 58: Diabetes Therapeutics Market, Global, Strategic Consolidation, 2004-2011
Table 59: Diabetes Therapeutics Market, Global, Number of M&A Deals by Value, 2004-2011
Table 60: Diabetes Therapeutics Market, Global, Mergers and Acquisitions, 2010-2011
Table 61: Diabetes Therapeutics Market, Global, Number of M&A Deals by Geography, 2004-2011
Table 62: Diabetes Therapeutics Market, Global, Number of M&A Deals by Indication, 2004-2011
Table 63: Diabetes Therapeutics Market, Global, Number of Licensing Agreements by Geography, 2004-2011
Table 64: Diabetes Therapeutics Market, Global, Licensing Agreements, 2010-2011
Table 65: Diabetes Therapeutics Market to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011
Table 66: Diabetes Therapeutics Market to 2017, Number of Licensing Agreements by Value, Global, 2004-2011
Table 67: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Geography, 2004-2011
Table 68: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals, 2010-2011
Table 69: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication, 2004-2011
Table 70: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Value, 2004-2011

1.2 List of Figures
Figure 1: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2017
Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2017
Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns, 2003-2017
Figure 4: Diabetes Therapeutics Market, Global, Prevalence Population, 2003-2017
Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population, 2003-2017
Figure 6: Diabetes Therapeutics Market, Global, Diagnosed Population, 2003-2017
Figure 7: Diabetes Therapeutics Market, Global, Prescription Population, 2003-2017
Figure 8: Diabetes Therapeutics Market, Global, Drivers and Restraints
Figure 9: Diabetes Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2010
Figure 10: Diabetes Therapeutics Market, The US, Revenue Forecasts, ($bn), 2003-2017
Figure 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2017
Figure 12: Diabetes Therapeutics Market, The US, Treatment Usage Patterns, 2003-2017
Figure 13: Diabetes Therapeutics Market, The US, Prevalence Population, 2003-2017
Figure 14: Diabetes Therapeutics Market, The US, Treatment Seeking Population, 2003-2017
Figure 15: Diabetes Therapeutics Market, The US, Diagnosed Population, 2003-2017
Figure 16: Diabetes Therapeutics Market, The US, Prescription Population, 2003-2017
Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2003-2017
Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2017
Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2003-2017
Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Prevalence Population, 2003-2017
Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population, 2003-2017
Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosed Population, 2003-2017
Figure 23: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population, 2003-2017
Figure 24: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2003-2017
Figure 25: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2017
Figure 26: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2003-2017
Figure 27: Diabetes Therapeutics Market, Japan, Prevalence Population, 2003-2017
Figure 28: Diabetes Therapeutics Market, Japan, Treatment Seeking Population, 2003-2017
Figure 29: Diabetes Therapeutics Market, Japan, Diagnosed Population, 2003-2017
Figure 30: Diabetes Therapeutics Market, Japan, Prescription Population, 2003-2017
Figure 31: Type 1 Diabetes Market, Global, Unmet Needs
Figure 32: Type 1 Diabetes Market, Global, Branded vs. Generic Market Share (%), 2010
Figure 33: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017
Figure 34: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017
Figure 35: Type 1 Diabetes Market, Global, Treatment Flow Algorithm
Figure 36: Type 1 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017
Figure 37: Type 1 Diabetes Market, Global, Prevalence Population, 2003-2017
Figure 38: Type 1 Diabetes Market, Global, Treatment Seeking Population, 2003-2017
Figure 39: Type 1 Diabetes Market, Global, Diagnosed Population, 2003-2017
Figure 40: Type 1 Diabetes Market, Global, Prescription Population, 2003-2017
Figure 41: Type 1 Diabetes Market, Global, Diabetes Market Drivers and Restraints
Figure 42: Type 2 Diabetes Market, Global, Unmet Needs
Figure 43: Type 2 Diabetes Market, Global, Branded vs Generic Market Share, 2010
Figure 44: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017
Figure 45: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017
Figure 46: Type 2 Diabetes Market, Global, Treatment Flow Algorithm
Figure 47: Type 2 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017
Figure 48: Type 2 Diabetes Market, Global, Prevalence Population, 2003-2017
Figure 49: Type 2 Diabetes Market, Global, Treatment Seeking Population, 2003-2017
Figure 50: Type 2 Diabetes Market, Global, Diagnosed Population, 2003-2017
Figure 51: Type 2 Diabetes Market, Global, Prescription Population, 2003-2017
Figure 52: Type 2 Diabetes Market, Global, Market Drivers and Restraints, 2010-2017
Figure 53: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
Figure 54: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
Figure 55: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011,
Figure 56: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2010
Figure 57: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2017
Figure 58: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2010
Figure 59: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2017
Figure 60: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Segment (%), 2010
Figure 61: Diabetes Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product (%), 2010
Figure 62: Diabetes Therapeutics Market, SWOT Analysis, Novo Nordisk
Figure 63: Diabetes Therapeutics Market, Sanofi, Revenue by Segment (%), 2010
Figure 64: Diabetes Therapeutics Market, Sanofi, Diabetes Revenue by Product (%), 2010
Figure 65: Diabetes Therapeutics Market, SWOT Analysis, Sanofi
Figure 66: Diabetes Therapeutics Market, Takeda, Revenue by Segment (%), 2010
Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Takeda
Figure 68: Diabetes Therapeutics Market, Eli Lilly, Revenue by Segment (%), 2010
Figure 69: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2010
Figure 70: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly
Figure 71: Diabetes Therapeutics Market, GSK, Revenue by Segment (%), 2010
Figure 72: Diabetes Therapeutics Market, SWOT Analysis, GSK
Figure 73: Diabetes Therapeutics Market, Merck, Revenue by Segment, 2010
Figure 74: Diabetes Therapeutics Market, SWOT Analysis, Merck
Figure 75: Diabetes Therapeutics Market, Amylin, Revenue by Segment (%), 2010
Figure 76: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2010
Figure 77: Diabetes Therapeutics Market, SWOT Analysis, Amylin
Figure 78: Diabetes Therapeutics Market, Global, Strategic Consolidation (%), 2004-2011
Figure 79: Diabetes Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011
Figure 80: Diabetes Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011
Figure 81: Diabetes Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2011
Figure 82: Diabetes Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011
Figure 83: Diabetes Therapeutics Market, Global, Licensing Agreements by Indication (%), 2004-2011
Figure 84: Diabetes Therapeutics Market to 2017, Global, Licensing Agreements by Value (%), 2004-2011
Figure 85: Diabetes Therapeutics Market to 2017, Global, Co-Development by Geography (%), 2004-2011
Figure 86: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication (%), 2004-2011
Figure 87: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals by Value (%), 2004-2011
Figure 88: Diabetes Therapeutics Market, GBI Research Market Forecasting Model

GBI Research, the leading business intelligence provider, has released its latest research “Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global diabetes therapeutics market. The report analyzes the markets for diabetes in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and prices are forecast up to 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Diabetes Therapeutics Market is Attractive despite Declining Sales of Actos and Avandia

GBI Research finds that the global diabetes therapeutics market is lucrative despite the declining sales of Actos and Avandia. The major factor driving the growth of the market is the rising prevalence rate of the diabetic population in key markets such as the US, the UK and Germany.

The global diabetes prevalence population in 2010 was estimated at 61.5 million, in which Type 1 diabetes was estimated at 7.2 million and Type 2 diabetes was estimated at 54.3 million. The Type 2 diabetes market accounted for 72% of the global diabetes therapeutics market. The diabetes market has also witnessed some product failures. Avandia (rosiglitazone), belonging to the class of thiazolidinedones, was found to increase the probability of heart risks. Following the discovery of the side effects, the sales of Avandia plunged alarmingly. The Avandia products recorded peak sales of $3 billion in 2006, falling to $572m in 2010. In addition, Actos (pioglitazone hydrochloride), another thiazolidinedone, acquired market share from Avandia, although it was also found to be associated with increasing risk of heart related complications. Nevertheless, the diabetes market still remained attractive due to increased utilization of other drugs such as insulin analogues and biguanides. At the same time, some of the promising molecules in the peptide analogues class are expected to be launched in the market.

GBI Research forecasts that the diabetes therapeutics market will grow at 7.1% between 2010 and 2017. The market will be primarily driven by the rising prevalence rates and the market entry of new products such as Teplizumab, Syncria, Alogliptin, Bydureon, Dapagliflozin, Canagliflozin, and some new molecules belonging to the peptide analogues class.

- Novo Nordisk
- Sanofi
- Takeda
- Eli Lilly
- GlaxoSmithKline (GSK)
- Merck & Co Inc
- Amylin Pharmaceuticals

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos